Published in Cancer Weekly, March 9th, 2004
The study will seek to enroll approximately 360 patients at up to 50 cancer centers across North America.
On February 2, 2004, the U.S. Food and Drug Administration (FDA) accepted for priority review the company's New Drug Application (NDA) to market RSR13 as an adjunct to whole brain radiation therapy for the treatment of brain metastases from breast cancer. The FDA has established a target date of June 4,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.